Project Grant R01MH140916
- The National Institute of Mental Health awarded The McLean Hospital Corporation $771,937 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the synaptic mechanisms underlying intermittent theta burst stimulation (ITBS) as a treatment for major depressive disorder. The research examines whether ITBS, an FDA-cleared patterned form of transcranial magnetic stimulation delivered clinically to the dorsolateral prefrontal cortex, works by enhancing...
- The National Institute of Mental Health awarded Massachusetts General Hospital $453,750 under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop a closed-loop system for assessing target network engagement using concurrent transcranial magnetic stimulation and functional MRI. The recipient is developing a flexible radiofrequency coil array (the RF Cap) that enables functional MRI acquisition simultaneously with transcranial magnetic stimulation in a...
- The National Institute of Mental Health awarded The Leland Stanford Junior University $1,066,793 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026, to develop and validate a personalized repetitive transcranial magnetic stimulation (rTMS) protocol for treatment-resistant depression using electrophysiological biomarkers. The award funds an R61/R33 phased study that will use early local TMS-evoked potentials (EL-TEPs)—measurements of prefrontal excitability—to...
- The National Institute of Mental Health awarded The Research Foundation for The State University of New York $437,125 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a preliminary positron emission tomography study quantifying the mechanism of transcranial magnetic stimulation in depression. The recipient, operating as Stony Brook University, will investigate the relationship between repetitive transcranial magnetic stimulation (rTMS)—an FDA-approved...
- The National Institute of Mental Health awarded Trustees of Dartmouth College $114,152 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research determining and enhancing the cellular selectivity of transcranial magnetic stimulation using optical physiology and computational models. The funded research directly tests predictions about how transcranial magnetic stimulation (TMS)—an FDA-approved treatment for drug-resistant depression,...
- The National Institute of Mental Health awarded $466,175 to Massachusetts General Hospital on August 11, 2026, under the Mental Health Research Grants program (CFDA 93.242) to map neuroimmune circuitry implicated in major depressive disorder and treatment-resistant depression. The recipient will conduct multimodal neuroimaging and anatomical research to elucidate circuits connecting limbic regions with the nucleus tractus solitarii in the brainstem, a neural pathway through which inflammatory...
- The National Institute of Mental Health awarded Ampa Inc. $3.168 million on September 15, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate a next-generation transcranial magnetic stimulation (TMS) system for scalable, personalized depression treatment. Ampa is engineering a portable TMS device that replicates the efficacy of Stanford Neuromodulation Therapy (SNT)—which achieves approximately 80 percent symptom remission in five treatment days—without...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Texas Health Science Center at Houston $1,125,194 under the Mental Health Research Grants program (CFDA 93.242) effective August 15, 2025, through August 14, 2027. This Project Grant funds a clinical research trial investigating the efficacy of bilateral repetitive transcranial magnetic stimulation (rTMS) targeting the prefrontal and insular cortices for treating comorbid depression in patients...
- The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
- The National Institute of Mental Health awarded Emory University $1,229,954 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct the PREVENT Study, a project grant focused on preventing chronic post-traumatic stress disorder and depression through early neurostimulation intervention. The award funds a two-year research initiative running through March 31, 2028, conducted in Georgia. The study targets emergency department patients who have experienced...
The National Institute of Mental Health awarded Brigham & Women's Hospital Inc. $863,825 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a double-blind, confirmatory efficacy trial comparing imaging-based targeting versus scalp-targeted accelerated transcranial magnetic stimulation (ATMS) for treatment-resistant major depressive disorder. The trial will enroll 120 participants to test whether imaging-targeted ATMS, using Stanford Accelerated Intelligent Neuromodulation Therapy (AINT) with patented functional connectivity-based targeting, produces significantly greater Montgomery-Asberg Depression Rating Scale (MADRS) improvement than conventional scalp-based targeting. A blinded pilot trial conducted in 2023 (N=21) showed 69.8 percent MADRS improvement in the imaging-targeted group versus 52.9 percent in the scalp-targeted group one month post-treatment. The proposed trial is powered at 99 percent to detect between-group differences based on these preliminary results. Primary aims include comparing clinical outcomes between treatment arms and assessing response rates (50 percent or greater MADRS improvement) across groups. The award funds research conducted at Brigham & Women's Hospital in Massachusetts. The period of performance runs from the award date through April 30, 2031. This is a Project Grant, the standard NIH R01 mechanism for investigator-initiated research in mental health.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $863.8k | 8/4/26 |